NHS: Drugs

Department of Health written question – answered on 21st March 2017.

Alert me about debates like this

Photo of Stephen Timms Stephen Timms Labour, East Ham

To ask the Secretary of State for Health, pursuant to the Answer of 23 January 2017 to Question 60583, on NHS: drugs, if he will publish those initial assessments.

Photo of Nicola Blackwood Nicola Blackwood The Parliamentary Under-Secretary of State for Health

Indication specific pricing enables multiple prices for a single medicine, dependent on the indication. Under an indication-based pricing system, companies would no longer be required to offer additional discounts on the price of a product in order to ensure that it was recommended for use in less-effective indications. It would therefore result in higher costs for the National Health Service, which may not be matched by gains in net patient outcomes. Indication specific pricing would also place a significant additional administrative burden on the NHS, particularly because of the need to track the use of medicines on an individual patient basis in a consistent way across the NHS in order to pay the correct price per dose to the pharmaceutical company. This would add to operational costs for the NHS.

Does this answer the above question?

Yes0 people think so

No0 people think not

Would you like to ask a question like this yourself? Use our Freedom of Information site.